New York, United States, September 2025 – Diego J. Garzón has started a new role as Chief Business Officer at Apertura Gene Therapy, where he will lead corporate strategy, business development, and partnerships to advance the company’s mission of pioneering next-generation genetic medicines.
Diego has been with Apertura Gene Therapy for more than two years, most recently serving as Vice President, Corporate Development, where he drove business development initiatives, corporate strategy, and alliance management. His contributions have been instrumental in positioning Apertura as a leading innovator in gene therapy by engineering AAV capsids, regulatory elements, and payloads to overcome current limitations in genetic medicine.
Before joining Apertura, Diego spent three years at Exicure as Vice President, Corporate Development and Strategy, where he was responsible for business development, competitive intelligence, and corporate strategy in the nucleic acid therapeutics space across oncology and neuroscience. He successfully built alliances and strategic partnerships that supported the company’s pipeline expansion.
Earlier, Diego held multiple leadership roles at Allergan over six years, advancing from Medical Affairs Director to Director of Scientific Assessment. In these roles, he oversaw in-licensing, acquisitions, and co-development evaluations across neuroscience, gastroenterology, liver, and gene therapy, while also leading medical affairs initiatives across the U.S. and international markets.
Diego began his career in medical affairs and scientific roles with Almirall, Bristol-Myers Squibb, and Schering-Plough, building expertise in therapeutic areas including diabetes, cardiovascular disease, COPD, women’s health, and oncology. His career also included early experience as a Pharmaceutical Research Analyst at Millennium Research Group, providing deep insights into global markets.
Complementing his corporate experience, Diego co-founded a financial trading startup in healthcare and has provided consulting expertise through engagements in both public and private sectors. His strong academic background includes a PhD in Neuroscience from McMaster University and an MBA from Cornell Johnson Graduate School of Management, equipping him with both scientific and business leadership expertise.
About Apertura Gene Therapy
Apertura Gene Therapy is a biotechnology company focused on opening new opportunities in gene therapy for treating debilitating diseases with limited options. The company pioneers next-generation AAV gene therapies by simultaneously engineering capsids, regulatory elements, and payloads to overcome barriers in genetic medicine. Founded on technologies from the Broad Institute and Harvard University, and supported by Deerfield Management Company, Apertura is headquartered at The Cure in New York City.
Read Also : When HR “Produces Nothing”: A Response to Jennifer Sey’s Anti-HR Vision
The Fine Balance: Navigating Work, Life, and Mental Wellbeing
Mind the Leadership Gap – From Learning to Real-World Impact
How the Adecco Group is empowering its employees for the future of work
